U.S. Construction Stock News

NasdaqGS:FOXA
NasdaqGS:FOXAMedia

How Investors May Respond To Fox (FOXA) Using Tubi’s New Ad Tech To Court Gen Z Viewers

In March 2026, Fox subsidiary Tubi announced a broad slate of new ad technology, Gen Z– and sports-focused original programming, and high-profile partnerships, including exclusive free F1 altcasts with Apple TV in the U.S., at the IAB NewFronts in New York. By tying advanced pause ads, contextual Scene Sense targeting, CTV-to-mobile Connected Conversions, and box office attribution with Fandango together, Tubi is positioning its free streaming platform as a data-rich, performance-focused...
NYSE:PKG
NYSE:PKGPackaging

A Look At Packaging Corp Of America (PKG) Valuation As Shares Show Mixed Recent Returns

Event context and recent performance snapshot Packaging Corporation of America (PKG) is drawing investor attention after recent share price moves, with the stock up about 0.5% over the past day but showing declines over the week, month, and past 3 months. See our latest analysis for Packaging Corporation of America. That 0.5% 1 day share price return sits against a weaker recent pattern, with the 30 day share price return of 7.7% and year to date share price return of 2.7% both in decline. At...
NasdaqCM:SGML
NasdaqCM:SGMLMetals and Mining

A Look At Sigma Lithium (SGML) Valuation After New Financing, Earnings And Multi Year Production Guidance

Earnings, guidance and new financing reshape the Sigma Lithium story Sigma Lithium (SGML) has just paired a US$100 million bank guarantee for its second Greentech plant with full year 2025 earnings and multi year production guidance, giving investors fresh data on growth plans and current financial performance. See our latest analysis for Sigma Lithium. At a share price of US$14.51, Sigma Lithium has seen a 21.7% 7 day share price return and 17.6% 30 day share price return after a Blue Orca...
NasdaqGS:ZYME
NasdaqGS:ZYMEBiotechs

Why Zymeworks (ZYME) Is Up 6.7% After FDA Fast Track Win And CFO Appointment

Zymeworks Inc. recently received U.S. FDA Fast Track designation for ZW191, its folate receptor-a–targeting antibody-drug conjugate, in advanced or metastatic platinum-resistant ovarian cancer, and formally appointed veteran biopharma finance executive Kristin Stafford as Chief Financial Officer on April 1, 2026. The combination of expedited regulatory support for ZW191 and the addition of a CFO with deep royalty and life sciences financing experience directly touches both Zymeworks’...
NYSE:SHW
NYSE:SHWChemicals

A Look At Sherwin-Williams (SHW) Valuation After Earnings Beat And Disappointing Guidance

Sherwin-Williams earnings jolt puts guidance under the microscope Sherwin-Williams (SHW) has come under pressure after an earnings release that paired 5.6% year on year fourth quarter revenue growth and an EBITDA beat with full-year EPS guidance that fell short of analyst expectations. See our latest analysis for Sherwin-Williams. At a share price of $316.39, Sherwin-Williams has seen softer recent momentum, with a 30-day share price return of 4.1% and a 90-day share price return of 7.0%. The...
NasdaqCM:SLNO
NasdaqCM:SLNOBiotechs

A Look At Soleno Therapeutics (SLNO) Valuation After Its Recent Share Price Surge

Soleno Therapeutics stock overview Soleno Therapeutics (SLNO) has drawn fresh attention after a sharp 32.3% one day move, capping a month gain of 31.7%. That kind of short term swing naturally raises valuation and risk questions for investors. See our latest analysis for Soleno Therapeutics. The sharp 32.3% one day share price return and 71.7% 7 day share price return come after a 10.8% year to date share price gain, set against a 1 year total shareholder return of about 25% decline and a...
NasdaqGS:IBOC
NasdaqGS:IBOCBanks

International Bancshares (IBOC) Valuation Check After Dividend Hike And Full Year 2025 Results

Dividend hike and full year results put International Bancshares in focus International Bancshares (IBOC) is back on investor radars after the board approved a $0.73 per share cash dividend, a 4.3% increase, alongside the release of full year 2025 financial results. See our latest analysis for International Bancshares. At a share price of $68.26, International Bancshares has seen a 1-day share price return of 0.72% and a 1-month share price return of 2.60%, while the 1-year total shareholder...
NYSE:BF.B
NYSE:BF.BBeverage

A Look At Brown Forman’s Valuation After Mixed Recent Share Price Performance

What Brown-Forman’s recent performance could signal for investors Brown-Forman (BF.B) has drawn fresh attention after a mixed run in its share performance, with a roughly 6% gain over the past month but a negative total return over the past year. Against that backdrop, investors are weighing the company’s US$3.9b in revenue, US$807m in net income, and a value score of 4, alongside longer term total return figures that have trailed shorter term moves. See our latest analysis for...
NYSE:TREX
NYSE:TREXBuilding

A Look At Trex Company (TREX) Valuation As New Marketing Campaign Expands Brand Reach

Trex Company (TREX) has kicked off an expanded 2026 marketing push, rolling out national TV spots, lifestyle and sports integrations, and high-profile sponsorships that put its wood-alternative outdoor products and TrexPro builder network in front of a wider audience. See our latest analysis for Trex Company. At a share price of $36.04, Trex has a 7 day share price return of 1.81% but a 1 year total shareholder return decline of 32.10%, suggesting recent marketing and financing updates are...
NasdaqGS:CROX
NasdaqGS:CROXLuxury

Crocs (CROX) Is Up 11.3% After Beating Q4 EPS And Revenue Estimates Has The Bull Case Changed?

On February 12, 2026, Crocs, Inc. reported quarterly results with earnings per share of 2.29 and revenue of US$957.64 million, both exceeding analyst forecasts. The simultaneous outperformance on both the top and bottom lines highlights how Crocs’ current business model is converting sales strength into earnings efficiency. We’ll now explore how this earnings and revenue beat may influence Crocs’ existing investment narrative around international expansion, DTC focus, and...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

A Look At Ondas (ONDS) Valuation After JCapital’s Critical Short Report

Ondas (ONDS) came under pressure after JCapital Research released a critical report questioning the company’s reliance on share-funded acquisitions, its path to profitability, and its governance practices, including significant CEO stock sales ahead of expected dilution. See our latest analysis for Ondas. The share price has pulled back 0.8% over the last day to US$9.52 after the short report, despite a strong 1 year total shareholder return that is more than 10x. This suggests recent...
NasdaqGS:CHCO
NasdaqGS:CHCOBanks

City Holding (CHCO) Valuation Check After Major Buyback Completion And Dividend Confirmation

Buyback completion and new repurchase plan frame City Holding’s latest moves City Holding (CHCO) has just wrapped up a share repurchase covering 5.64% of its stock for US$93.8 million and launched a new program authorizing up to 1,000,000 additional shares, alongside affirming its regular quarterly dividend. See our latest analysis for City Holding. Those buybacks and the affirmed dividend come after a period where the 1 year total shareholder return of 14.83% has outpaced the more modest 3...
NYSE:LXU
NYSE:LXUChemicals

A Look At LSB Industries (LXU) Valuation After A Strong 12 Month Share Price Run

Context for LSB Industries stock LSB Industries (LXU) has drawn fresh attention after a strong year of share price performance, with total return over the past 12 months at 185% and market value around US$1.1b. See our latest analysis for LSB Industries. At a share price of US$15.00, LSB Industries has seen strong positive momentum over the past year, with a 68.35% 3 month share price return contributing to a 184.63% 1 year total shareholder return, even after a softer 7 day share price...
NasdaqCM:CPRX
NasdaqCM:CPRXBiotechs

Assessing Catalyst Pharmaceuticals (CPRX) Valuation After Recent Share Price Momentum

Why Catalyst Pharmaceuticals (CPRX) Is On Investors’ Radar Catalyst Pharmaceuticals (CPRX) has attracted attention after recent share moves, with the stock last closing at $24.98 and showing positive total returns over the past year and past 3 months. Investors are also weighing the company’s value score of 6 and its US$3b market cap, as well as its focus on commercial treatments for rare diseases through products such as Firdapse, Fycompa, and AGAMREE. See our latest analysis for Catalyst...
NasdaqGS:INCY
NasdaqGS:INCYBiotechs

Incyte (INCY) Valuation Check As New Povorcitinib Phase 3 Data Draws Investor Interest

Incyte (INCY) is back in focus after releasing 54 week Phase 3 data for its JAK1 inhibitor povorcitinib in moderate to severe hidradenitis suppurativa, alongside ongoing regulatory reviews in the US and Europe. See our latest analysis for Incyte. Alongside the new povorcitinib data and fresh collaboration and leadership updates, Incyte’s 7 day share price return of 5.01% contrasts with a 90 day share price return decline of 11.06%, while the 1 year total shareholder return of 57.34% points to...
NYSE:TYL
NYSE:TYLSoftware

A Look At Tyler Technologies (TYL) Valuation After Buyback Approval And Michigan Public Safety Deal

Tyler Technologies (TYL) is back in focus after approving a $200 million stock repurchase plan and securing a broad public safety software deployment across multiple Michigan counties, together drawing attention to both capital allocation and contract momentum. See our latest analysis for Tyler Technologies. The latest 1 day share price return of 0.25% and 30 day share price return of 9.98% sit within a tougher backdrop, with a 12 month total shareholder return of 36.98% and 5 year total...
NasdaqGS:EXEL
NasdaqGS:EXELBiotechs

Do Upgraded 2026 Earnings Forecasts Alter the Growth Narrative for Exelixis (EXEL)?

In recent weeks, Exelixis, the Alameda-based oncology biotech, has seen several Wall Street analysts raise their earnings estimates for fiscal 2026, citing improving expectations for the business. This cluster of upward revisions, combined with Exelixis’ A-rated VGM Score and focus on difficult-to-treat cancers, has reinforced its appeal to investors who closely track analyst models and valuation metrics. Next, we’ll explore how this wave of upgraded earnings forecasts could influence...
NasdaqGS:OKTA
NasdaqGS:OKTAIT

Why Okta (OKTA) Is Up 6.7% After Bullish Calls Highlight Its AI Agent Security Role – And What's Next

In early April 2026, Okta attracted fresh attention after a prominent TV analyst endorsed adding to positions and another firm upgraded the stock to a strong buy, citing durable identity-security demand and a growing role in protecting AI agents in enterprises. This renewed focus on Okta’s potential to secure AI agents highlights how identity management may become a critical control point as companies operationalize AI internally. Next, we’ll examine how Okta’s emerging AI agent security...
NYSE:GM
NYSE:GMAuto

General Motors (GM) Valuation Check As EV Job Cuts Meet New US$6b Buyback And Higher Dividend

General Motors (GM) is back in focus after cutting more than 1,000 jobs at its Factory Zero EV plant in Detroit, while simultaneously launching a new US$6b share repurchase and increasing its quarterly dividend. See our latest analysis for General Motors. At a share price of US$73.43, GM has seen a 1-day share price return of 1.23% and a year to date share price decline of 9.32%, while its 1-year total shareholder return of 70.40% suggests strong longer term momentum despite a softer 90-day...
NYSE:LBRT
NYSE:LBRTEnergy Services

Has Liberty Energy (LBRT) Run Too Far After A 170% One Year Share Price Surge

This article explores whether Liberty Energy's share price still reflects good value, or if the easier gains may already have occurred, by considering what the current price might be implying about the company. Liberty Energy closed at US$27.67, with a 4.1% decline over the last 7 days, a 3.2% gain over 30 days, a 46.6% return year to date, and a 169.7% return over the past year. Recent coverage has focused on Liberty Energy as part of broader discussions around US energy services companies...
NYSE:STZ
NYSE:STZBeverage

A Look At Constellation Brands (STZ) Valuation After Its Earnings Miss And Guidance Reaffirmation

Constellation Brands (STZ) is back in focus after its latest earnings release, where revenue and earnings came in below expectations but full-year guidance was reaffirmed, prompting an initial share drop followed by a recovery. See our latest analysis for Constellation Brands. At a share price of $155.25, Constellation Brands has seen short term momentum build, with a 1 month share price return of 5.99% and a 90 day return of 8.08%. However, its 1 year total shareholder return of 7.71% and 3...
NYSE:CCL
NYSE:CCLHospitality

Carnival’s Sensory Certified Destination Aims To Deepen Loyalty And Support Returns

Carnival Cruise Lines' Celebration Key has become the first cruise destination to earn KultureCity sensory inclusion certification. More than 400 team members have been trained to support guests with invisible disabilities, including autism and PTSD. This move broadens accessibility standards within cruise travel and may influence expectations across the wider travel sector. Carnival Corporation & (NYSE:CCL), trading at $25.97, is bringing a fresh angle to its brand with this accessibility...
NYSE:LOB
NYSE:LOBBanks

Should Live Oak Bancshares’ Revenue Beat but Earnings Miss Require Action From Live Oak Bancshares (LOB) Investors?

In the past few days, Live Oak Bancshares reported quarterly results showing revenue rising 16.8% year on year and beating analyst expectations, while earnings per share and tangible book value per share came in below forecasts amid continued regional banking sector pressures. This combination of stronger top-line growth but weaker bottom-line metrics highlights how funding costs, credit quality, or operating expenses can weigh on overall profitability even as loan and fee income...
NasdaqGS:CPRT
NasdaqGS:CPRTCommercial Services

A Look At Copart (CPRT) Valuation After Earnings And Revenue Miss Analyst Estimates

Copart (CPRT) recently reported quarterly earnings per share of US$0.36 on revenue of US$1.12b, both below analyst expectations. This has brought fresh attention to how temporary insurance related volume headwinds might affect the stock. See our latest analysis for Copart. At a share price of US$32.84, Copart’s 30 day share price return of 13% and year to date share price return of 13.05% point to fading short term momentum. The 1 year total shareholder return of 39.43% contrasts with a 5...